TGA issues new guidance on compounding

New compounding guidance outlines restrictions and expectations for “higher risk” products including GLP-1s and medicinal cannabis  Pharmacists are being urged to review new guidance from the Therapeutic Goods Administration (TGA) to ensure their compounding, supply and advertising practices comply with legal and professional requirements and any applicable exemptions.  The regulator warned that it would it would take action against